NEW YORK, June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia.
BioNeMo provides researchers and developers a fast and easy way to build and integrate state-of-the-art generative AI applications across the entire drug discovery pipeline—from target identification to lead optimization—with AI workflows. With the help of SRL, Hoth Therapeutics will have the ability to identify, create and leverage its pipeline for additional therapeutics and to further increase value of its assets.
Robert Antofe of Wise Systems International SRL commented, "We're excited to work with Hoth and leverage our existing AI expertise to help bring further value to both companies through the development of Hoth Therapeutics AI initiatives."
"We believe the Nvidia BioNeMo platform is best in class and with SRL's assistance we can better grow our IP, leverage our existing pipeline and deliver exciting novel therapeutics to patients in need," said Robb Knie, Chief Executive Office of Hoth Therapeutics.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Investor Contact:
LR Advisors LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
www.hoththerapeutics.com
Phone: (678) 570-6791
| Last Trade: | US$1.53 |
| Daily Volume: | 464,463 |
| Market Cap: | US$20.290M |
October 08, 2025 October 07, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
